Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.34 |
| ▸ | HTR2A | P28223 | 7/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044712 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL4041758 | 0.98 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL4041767 | 0.98 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4043084 | 0.90 | HTR2C (0.35) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4043381 | 0.90 | HTR2C (0.35) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4039422 | 0.88 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4039430 | 0.88 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL4042025 | 0.84 | HTR2A (0.32) | HTR2CHTR2A | |
| SCHEMBL4042031 | 0.84 | HTR2A (0.32) | HTR2CHTR2A | |
| SCHEMBL5357231 | 0.82 | HTR2C (0.55) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | claimed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | SLC6A2 323/4885SLC6A4 519/4885SLC6A3 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.